gold bar

MHIN is led by a volunteer board of directors that oversees meeting organization and general operations.

Our board currently consists of the following MHIN members:

Margarita Chavez, Co-President of the Board  
Director, Ventures & Early Stage Collaborations, AbbVie Inc.

Margarita Chavez has nearly 20 years of dealmaking experience. She has been in her current role since 2010 (then Abbott Biotech Ventures), leading close to a dozen investments and managing portfolio companies in the US and Europe. Before joining AbbVie Ventures, Ms. Chavez was a Director in Abbott’s Global Pharmaceutical Licensing & Acquisitions Division. Prior to that, Margarita was Senior Counsel in Abbott’s Legal Division. Margarita started her career as a corporate and securities lawyer in Silicon Valley and practiced with the firm of Brobeck Phleger & Harrison.

Nicole Walker, Co-President of the Board  
Baird Capital

Nicole joined Baird Capital with nearly 20 years of operational and investment experience in the Healthcare industry, particularly in medical devices and diagnostics.  Based in Chicago, Nicole was previously Director of Venture Investments for Abbott Ventures and Abbott Biotech Ventures, where she was responsible for the evaluation and management of equity investments in emerging healthcare companies; and before that, served in an operating role in Global Strategic Marketing in Abbott’s diabetes division.

Prior to Abbott, Nicole spent three years as a Principal with ONSET Ventures where she specialized in seed and early-stage medical technology investments and nearly ten years with Guidant Corporation where she held multiple roles in its R&D, Reliability, and lastly as the Head of Marketing, Asia for the Vascular Division.  Nicole is a member of the Midwest Healthcare Investors Network, Chicago Innovation Mentors, and serves as a Board Director in multiple private companies.

Nicole holds a bachelor’s degree in Mechanical Engineering from Stanford University, as well as MBA and Masters of Engineering Management degrees from Kellogg and Northwestern University.

George Arida  
Venture Investors

George Arida is a managing Director with Venture Investors LLC, with a focus on early-stage opportunities in the biotechnology, medical device, and agriculture sectors.

George currently serves as the Board Chair for Chromatin, Inc., Celleration, Inc., and Juventas Therapeutics, and served as Board Chair of Zystor Therapeutics (acquired by BioMarin Pharmaceutical Inc. – NASDAQ:BMRN) and Nerites Corporation (acquired by Kensey Nash) and also currently serves as member of the Board of Directors at NanoBio Corporation.  He is also a founding Director of the Mid-America Healthcare Investors Network, an association of over forty regional venture capital firms active in early stage healthcare investing.

George previously served as the CFO for a financial consulting and brokerage firm.  Prior to this, he spent five years at U.S. Filter Corporation in management and technical marketing positions, four years with Betz Laboratories in technical sales and field service management, and two years at Alar Engineering as a Process Engineer.  George has a bachelor of Science degree in Chemical Engineering from the University of Illinois at Urbana-Champaign and a Master of Business Administration degree with high honors from the University of Chicago.

Dan Broderick  

Dan Broderick has over 22 years of experience in the life sciences and venture capital industry. Prior to joining Prolog Ventures in 2007, Dan spent 7 years with Mason Wells Biomedical Fund as a Managing Director where he was responsible for all aspects of investment activities. While at Mason Wells, Dan served as a member of the Board of Directors of several portfolio companies including Gala Biotech, Mezzia, OpGen, Deltanoid Pharmaceuticals and ZyStor Therapeutics.

Prior to Mason Wells, Dan spent 18 years at Mayo Clinic in Rochester, Minnesota, where for 12 years he served as Director of the Office of Technology Commercialization. He has personally evaluated the commercial potential of hundreds of technologies in virtually every medical specialty. He has been directly responsible for negotiating and consummating over 100 medical technology commercialization agreements. He has experience with technology evaluation, market assessment, negotiations, academic institution technology transfer, and intellectual property management.

Dan played a key role in the launch of Mayo Clinic’s $25 million venture investing program. He co-founded and served on the Board of Directors of IntraTherapuetics, Inc., CNSoftware, and Medintell, Inc. In 1994, Dan was honored with an appointment to the Staff of Mayo Clinic.

Dan is actively involved in the venture capital community on a regional and national level. He served on the Board of Directors of the National Venture Capital Association (NVCA). He has testified before the U.S. Congress on behalf of the NVCA; works on a number of NVCA committees, and Chaired the Research Committee. Dan is the founder of the Mid-America Healthcare Investor Network (MHIN) and currently serves as President of the organization. He also is the past President of the Wisconsin Biotechnology and Medical Device Association, sat on the Advisory Boards of the University of Minnesota’s Office of Business Development, and BioGenerator in St. Louis, Missouri. He also served as a member of the Board of Trustees for the Medical College of Wisconsin Research Foundation and the University of Wisconsin – Milwaukee Research Foundation.

Dan received a Bachelors Degree in Biology from Iowa State University in 1982. He has completed some graduate course work in Finance, Accounting, and Marketing at Winona State University.

Michael Fulton, MD  
Hopen Life Sciences

Michael Fulton has over 20 years’ experience in the life sciences space, including 14 years as a successful early stage investor and entrepreneur. Prior to joining Hopen, Mike served in the roles of founder, director, and CEO at startup medical device and services companies, including Lanx, Inc., the second largest private company in the $7B spinal implant market. As CEO of Lanx, he built the organization from a single employee, pre-revenue company into an international corporation with over 200 employees. His accomplishments included raising over $50M in equity and venture debt, building a world-class team of medical device professionals, and launching an innovative fusion product that advanced a new paradigm in spinal treatment. Mike also played a key leadership role, served on the Board, and helped raise over $46M of equity for ProNerve, LLC, an Intraoperative Monitoring company he co-founded in 2007. Mike is an inventor of multiple neurosurgical and spinal devices with over 50 issued and pending U.S. and international patents. He received his B.A. from Northwestern University, his M.D. from Cornell University Medical College, and completed two years of neurosurgery residency at the Cleveland Clinic.

Anna Haghgooie  
Sandbox Industries

Anna Haghgooie is a Managing Director of Sandbox Industries, where she focuses on investing in healthcare innovation through the BlueCross BlueShield Venture Funds. She serves on the Board of Directors of Change Healthcare, ZeOmega, naviHealth and Everymove. Before joining Sandbox, Anna was the General Manager at an integrative healthcare start-up where she helped the company streamline operations and prepare for growth. Previously she held positions as an Associate Director of Corporate Finance at Fitch Ratings covering the Healthcare Sector and as a member of the Financial Management Program at General Electric. Anna holds a BBA from the University of Michigan Ross School of Business and an MBA with Honors from the University of Chicago Booth School of Business.

David Kereiakes  
River Cities Capital Funds

David Kereiakes is an investment professional with River Cities Capital Funds, a growth equity firm that invests in healthcare and technology companies. David emphasizes his investment practice on the Firm’s healthcare portfolio. David currently serves on the Board of Directors of Veran Medical while also working closely with portfolio clients, TissueTech, OrthAlign, Advanced Practice Strategies, and NICO Corp among others. Prior to joining River Cities, David served as an associate with American Financial Group, a registered principal and independent investment adviser and completed extensive training programs with Merrill Lynch and Procter & Gamble. David graduated with a Bachelor of Science in Finance from Indiana University’s Kelley School of Business and received his Master of Business Administration with a concentration in Finance from Xavier University’s Williams College of Business.

Peter Kleinhenz  
CID Capital

Peter Kleinhenz has been actively involved in the life sciences sector as an entrepreneur, consultant, or professional investor for over 25 years. He is a Venture Partner of Fletcher Spaght Ventures headquartered in Boston, MA and leads their Ohio office. He joined FSV in 2009 and represents FSV’s investment in SurgiQuest, Inc. and Cayenne Medical, Inc.

Peter is also a Managing Director of CID Capital, Inc. a thirty-two year old venture capital and private equity firm headquartered in Indianapolis, IN.  He is a director or observer for the following CID portfolio companies: AxioMed Spine Corporation, RedPath, Inc. and MedVantx, Inc. His exits include Ekos Corporation (acquired by BTG, PLC), Renal Solutions (acquired by Fresenius Medical Care), and Qorval Integrated Solutions, Inc. (acquired by Abeam Consulting).

Prior to joining CID Capital in 2001, Peter served as Vice President of Commercialization– Life Sciences for Battelle Memorial Institute working in their medical device, pharmaceutical and toxicology sectors.

He was CEO and principal owner of Progenics Inc., a product development and pilot manufacturing company for medical products and industrial controls, which he sold in 1997. He was part of the founding business team of Neoprobe Corporation a biotech and medical device company focused on cancer detection and therapy.  As CFO and VP of Finance and Administration he raised over $12M of venture capital. He also served as Vice President of Strategic Planning and Business Development.
Since 1991 he has been a board member of Ohio’s life science organization BioOhio serving as Chairman in 2010 and a member of the Executive Committee since 1993.  He is the founder and serves as chairman of the MHIN’s Midamerica Healthcare Investment Forum. He is on the Visiting Committee at the Weatherhead School of Management, Case Western Reserve University and serves The Ohio State Medical Centers Technology Commercialization Committee and the Ohio Healthcare Information Partnership board of trustees.

Peter received an MBA from Case Western Reserve University, a bachelor's degree from Loyola University of Chicago, and is a Certified Public Accountant (inactive status) in Ohio.

Paul McCreadie  
Arboretum Ventures

Paul McCreadie joined Arboretum Ventures in 2006 as an Associate and became a Managing Director in 2011.

Paul invests in capital-efficient medical technology, service, and health IT companies focusing on the application of innovative technologies to underserved markets. His technical background in engineering provides a foundation for assessing product development risks and assisting portfolio companies with new product introductions. Paul is the former Chief Operating Officer for CerviLenz, an Arboretum portfolio company based in Ohio, where he led the re-design of the company’s first commercial product from concept to launch. In his time with Arboretum, Paul has held board responsibilities for more than six portfolio companies and has led three investments.

Prior to joining Arboretum, Paul worked at Ford Motor Company for eight years, holding management positions within new product development, manufacturing, and business strategy. He was an associate with the Wolverine Venture Fund (WVF) while an MBA student at Michigan's Ross School of Business.

Kathleen Tune  
Thomas, McNerney & Partners

Kathleen has been president since 2012. She joined Thomas, McNerney & Partners from Piper Jaffray, where she was a health care analyst focused on medical technology companies. While at Piper, Kathy covered over 20 companies in the medical device, medical supply and diagnostic areas. Her background also includes experience in new product development at Solvay, S.A. (in a division that is now part of Pfizer). Projects at Solvay included the development of vaccines for the prevention of viral infections. Kathy was also a Senior Scientist in molecular biology at the University of Minnesota, where she worked on the development of molecular biology based assays for the detection of infectious agents. Kathy is currently a board member of CAS Medical Systems, Inc. (CASM) and VertiFlex, Inc. Kathy serves or has served in advisory roles to portfolio companies Torax Medical, Inc. and Atritech, Inc. She is also the President of the Mid-America Health Care Investors Network (MHIN), a member of the American Heart Association's Advancing Sciences Executive Leadership Team, and a member of the Advisory Board for the Carlson Fund Enterprises at the University of Minnesota's Carlson School of Management. Her educational background includes an M.S. degree in Microbiology from the University of Minnesota and an M.B.A. from the University of Minnesota's Carlson School of Management, where she was a Robert and Gail Buuck Scholar.

Michael Wasserman  
H.I.G. BioVentures

As a Managing Director at H.I.G. BioVentures, Michael Wasserman focuses on investment opportunities in the life sciences sector, including biopharmaceuticals and medical devices. Michael currently represents H.I.G. on the boards of: HyperBranch Medical Technology, Clarus Therapeutics, CardioFocus and NeuWave Medical.

Prior to joining H.I.G., Michael was with Innovations Foundation, where he focused on the creation, financing and development of high technology companies in the life sciences, information technology and engineering sectors. At Innovations Foundation, Michael was instrumental in building multiple high growth companies derived from academic or federally sponsored research programs. Michael was a Founder of CELLutions Biosystems (acquired by Cedarlane Laboratories), where he broadly managed business operations and was directly responsible for the successful negotiation of partnership, co-development and licensing agreements with industry leading pharmaceutical and biotechnology organizations. As Director of Research at Advanced Therapeutics, Michael was involved in a series of seminal clinical studies involving biological approaches to treat rheumatoid arthritis and other autoimmune and inflammatory disorders.

Michael received his B.Sc. from McGill University and his Ph.D. in Pharmacology from the University of Toronto.


Member List >